EUVIMEDEUVIMED entdecken
Fallbericht

Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years

Patrick H Hosie, Carylyn Lim, Timothy R D Scott, Michael Cardamone, Michelle A Farrar, Catherine Frith, Peter I Andrews, Jason Pinner, Sekhar Pillai

Brain and Development · 2023

DOI: 10.1016/j.braindev.2023.03.002 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Brain and Development, 2023. Verfasst von Patrick H Hosie und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Sydney Children's Hospital, Randwick, Australia. Hauptthemen laut MEDLINE: Interleukin-6, Brain Diseases. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acute necrotizing encephalopathy (ANE) of childhood is a rare and devastating infection-associated acute encephalopathy. While there are no consensus treatments for ANE, recent case reports suggest a beneficial role for the use of tocilizumab, a recombinant humanized monoclonal antibody against the interleukin-6 (IL-6) receptor. The correlation of the timing of add-on tocilizumab in relation to long-term outcome has not been reported. METHODS: We report on the timing of administration of tocilizumab in two patients classified as high-risk using the ANE severity score (ANE-SS) with respect to the long-term outcome at 2 years. RESULTS: Case 1 was a 19-month-old previously well boy who presented to a tertiary children's hospital with seizures, evolving status dystonicus and shock. Case 2 was a three-year-old boy who presented to a peripheral hospital with fever, sepsis and encephalopathy. The patients were transferred to the tertiary intensive care unit and MRI confirmed ANE with extensive brainstem involvement. Case 1 received intravenous immunoglobulin (IVIg), methylprednisolone and tocilizumab at 21, 39 and 53 h respectively. His modified Rankin scale (mRS) at discharge and two years was unchanged at 5. The functional independence measure - for children (WeeFIM) at two years was very low (19/126). Case 2 received dexamethasone at 1 h, methylprednisolone at 21 h and IVIg and tocilizumab at 22 h. The mRS at discharge and two years was 4 and 3 respectively. The WeeFIM score at two years showed substantial improvement (96/126). CONCLUSION: The very early use of interleukin-6 blockade as 'add-on' immunotherapy in the first 24 h demonstrates potential for improving the long-term outcome in patients classified as high-risk using the ANE-SS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Brain DiseasesMaleChildHumansChild, PreschoolInfantImmunoglobulins, IntravenousImmunotherapyMethylprednisoloneReceptors, Interleukin-6

Stichwörter der Autor:innen

Acute necrotizing encephalopathy of childhoodEncephalitisImmunotherapyInterleukin 6Long-term outcomeNeurorehabilitationTocilizumab

Substanzen

Interleukin-6Immunoglobulins, IntravenousMethylprednisoloneReceptors, Interleukin-6

Autor:innen und Institutionen

  • Department of Neurology, Sydney Children's Hospital, Randwick, Australia.
  • Rehab2Kids, Sydney Children's Hospital, Randwick, Australia.
  • Rehab2Kids, Sydney Children's Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia; Graduate School of Biomedical Engine…
  • Department of Neurology, Sydney Children's Hospital, Randwick, Australia; Discipline of Pediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia.
  • Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, Australia.
  • Centre for Clinical Genetics, Sydney Children's Hospital, Randwick, Australia.

Zitieren

APA

Hosie, P. H., Lim, C., Scott, T. R. D., Cardamone, M., Farrar, M. A., Frith, C., Andrews, P. I., Pinner, J., & Pillai, S. (2023). Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years. Brain and Development. https://doi.org/10.1016/j.braindev.2023.03.002

Vancouver

Hosie PH, Lim C, Scott TRD, Cardamone M, Farrar MA, Frith C, et al. Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years. Brain and Development. 2023. doi:10.1016/j.braindev.2023.03.002

BibTeX
@article{Hosie2023,
  author = {Hosie, Patrick H and Lim, Carylyn and Scott, Timothy R D and Cardamone, Michael and Farrar, Michelle A and Frith, Catherine and Andrews, Peter I and Pinner, Jason and Pillai, Sekhar},
  title = {Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years},
  journal = {Brain and Development},
  year = {2023},
  doi = {10.1016/j.braindev.2023.03.002}
}
Kostenlos starten →